Insulin Treatment in Diabetic Older People With Heart Failure.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-08

Study Completion Date

2019-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiac failure (HF) and type 2 diabetes mellitus (T2DM) are two clinical conditions with a significant impact on public health worldwide. In the elderly population the prevalence of T2DM is constantly increasing as well as its incidence in all Western countries including Italy. The combination of HF and T2DM is frequent and leads to an increased risk of death and of non-fatal adverse cardiovascular (CV) events which justifies the frailty of this population. Although diabetic patients (pts) with HF respond to recommended treatments for HF, the effective and safe control of blood glucose levels is still an outstanding clinical problem, since glucose lowering drugs may increase the risk of CV adverse events. Insulin, used in about 30% of diabetic patients with HF, causes adverse effects such as fluid and sodium retention and unwanted effects of hypoglycemia. Even if insulin remains a milestone in glucose lowering therapy of T2DM, its risk/benefit ratio is still controversial, more so when given to old patients with HF. The issue has gained relevance since new antidiabetic agents, as the sodium glucose co-transporter 2 (SGLT- 2) inhibitors and glucagon-like peptide (GLP-1) analogues, with a safer CV profile have been made available. While the transferability of the CV benefits attributed to the new drugs needs to be assessed in clinical practice, the present study explore the benefit/risk profile of insulin in HF.

Objectives: to assess comparatively in patients with heart failure and T2DM the benefit/risk profile over 1-year follow-up of two antidiabetic strategies, standard care with vs without insulin in terms of humoral and clinical endpoints including body weight change, all-cause mortality and burden of care components (hospitalizations for CV events and episodes of severe hypoglycemia).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Incretin-based Drugs and the Risk of Heart Failure

NCT02456428

Type 2 Diabetes Mellitus

COMPLETED

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506

Diabetes Mellitus, Type 2

COMPLETED

Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

NCT05335629

Myocardial Infarction Diabetes Mellitus, Type 2 Myocardial Remodeling, Ventricular

COMPLETED NA

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

NCT04385589

Heart Failure

COMPLETED PHASE4

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

NCT02397421

Heart Failure Diabetes

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The project will consist in a controlled, randomized, open-label (PROBE design) multicenter, pilot study. Central randomization stratified by center, performed online, will allow a comparison of two groups of patients one receiving standard care including insulin, the other standard care without insulin. Patients considered not eligible for randomization will be included in a registry.

The first objective of this exploratory randomized study is to assess in patients with heart failure and T2DM if a standard anti-diabetic strategy which includes insulin has a different safety and efficacy profile than one without insulin. The number of patients to be included in this exploratory pilot study will be insufficient to prove or disprove a statistically significant beneficial effect of the two antidiabetic strategies on clinical events. Special care will be paid to the biologic consistency of the different endpoints, primary and secondary, even if none of them will individually yield statistically significant differences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The primary endpoint, glucose variability, will be computed from 3 daily glucose profiles performed before the baseline, 1, 6, 12 mo follow-up and at end study visit and calculated as the average of the three daily standard deviations. Blood glucose values will be reported by the patient in an ad hoc form and the responsible physician will input this data in the e-CRF.

An intensive ambulatory self-monitoring of weekly body weight and possible changes in diuretic treatment is required.

At 1, 6, 12 mo of follow up and/or at end of study visit:

1. patients will be examined,
2. the information about clinical events will be collected.
3. natriuretic peptide plasma concentration, HbA1c and urinary albumin excretion will be measured Echocardiographic evaluation will be done at baseline, 1 and 12 mo after randomization.

Central randomization in a 1:1 ratio will be performed by a web-based system.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Insulin-HF is a randomized, open-label, controlled, multicenter (PROBE design, prospective Randomized Open Trial with Blinded Evaluation of Outcomes), and central adjudication of adverse events.

All study events, clinical and laboratory, will be independently validated by an Event Committee

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

non insulin

standard care + antidiabetic therapy non insulin

Group Type NO_INTERVENTION

No interventions assigned to this group

Insulin

standard care including insulin

Group Type EXPERIMENTAL

Insulin

Intervention Type DRUG

Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.

The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin

Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.

The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. men and women aged ≥70 years;
2. at discharge after admission to hospital for worsening of HF or ambulatory patients with chronic HF;
3. New York Heart Association (NYHA) class II or III
4. with any level of left ventricular ejection fraction;
5. plasma natriuretic peptide (BNP) ≥200 pg/mL or N-terminal pro-BNP ≥900 pg/mL (NT pro-BNP)
6. prior history or newly diagnosed T2DM;
7. candidate by the responsible physician to insulin therapy;
8. signed informed consent.

Exclusion Criteria

1. significant renal insufficiency (GFR \<30 mL/min/1.73 m2) or severe liver disease (liver function test abnormalities (alanine or aspartate aminotransferase ≥ 3 × upper limit of normal \[ULN\]);
2. levels of hemoglobin \<10 g/dl;
3. HbA1c ≤5% or ≥11%;
4. unstable diabetes: type of diabetes presentation in patients with an anamnesis of frequent episodes of hypoglycemia, hyperglycemic hyperosmolar state, ketoacidosis or lactic acidosis;
5. planned CV surgery or angioplasty in 3 months;
6. any non-cardiac disease that shortens life expectancy to\<1 year (e.g.most cancers);
7. inability to comply with study protocol;
8. participation to another interventional clinical study.

Minimum Eligible Age

70 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No